All articles by
Roche’s Ocrevus was non-inferior to IV infusion, offered near-complete B-cell depletion, finds study
As per the results, the investigational twice-yearly, 10-minute subcutaneous injection was found non-inferior as measured by Ocrevus levels in the blood of patients from day one to 12 weeks
Cirdan Ltd secures £2.3m to expand operations in New Funding Round Led by Kernel Capital
Lisburn based Cirdan, is a global leader in digital pathology with clients in over 150 laboratories and hospitals across 20 countries and 6 continents. The Company is growing its revenues with expected 80%+ year on year growth in 2024. Cirdan has successfully secured £2.3m in new funding to expand business operations with the creation of up to 25 new jobs ahead of new contract wins. The investment was led by Kernel Capital through the Bank of Ireland Kernel Capital Growth Fund (NI). Other investors include Clarendon Fund Managers and high net worth private investors.
BioMap, Sanofi to jointly develop AI modules biotherapeutic drug discovery
The collaboration will leverage BioMap’s AI drug discovery platform, which integrates large language models and super-scale computing with advanced biotechnology to discover novel targets, design biologics, and optimise multiple parameters
Theramex Announces Agreement to Acquire the European Rights to Duphaston and Femoston From Viatris
The transaction is subject to customary regulatory and anti-trust approvals
Gates Foundation announces $40m funding to advance mRNA-based vaccines
The Bill & Melinda Gates Foundation will provide $20m to Quantoom Biosciences to further advance the mRNA technology, and $5m each to Institut Pasteur de Dakar (IPD) and Biovac to purchase and use the technology to develop the vaccines locally
Amgen concludes $27.8bn acquisition of Horizon Therapeutics
The deal has secured clearance from the US Federal Trade Commission which prohibits Amgen from using any anti-competitive strategies to prolong the market domination of Tepezza and Krystexxa
Novartis gets FDA nod for Cosentyx IV formulation for rheumatic diseases
The FDA has cleared Cosentyx as the first IV formulation interleukin-17A antagonist for adults with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis
FDA Approves TOFIDENCE (tocilizumab-bavi) a Biosimilar of ACTEMRA developed by Bio-Thera Solutions
TOFIDENCE is the first monoclonal antibody drug researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States
FDA Grants Orphan Drug Designation to GC Biopharma’s Drug Candidate for Thrombotic Thrombocytopenic Purpura
When designated as an orphan drug, there are incentives such as tax credits for clinical development costs and exemptions from PDUFA user fees Initial Pediatric Study Plan
AbbVie completes acquisition of Parkinson’s focused Mitokinin
The deal includes Mitokinin’s lead asset, a selective PINK1 activator, which is designed to mitigate mitochondrial dysfunction factor that is believed to support PD pathogenesis and progression